Imiquimod 5% cream in the treatment of superficial and nodular basal cell carcinomas: Study of 10 cases;Tratamento tópico do carcinoma basocelular superficial e nodular pelo imiquimod creme a 5%: Observação de 10 casos

Anais Brasileiros de Dermatologia

Volumn 77, Issue 6, 2002, Pages 693-698

  Neto, Cyro Festa ^a  

^a NONE

Author keywords

Adjuvants; Basal cell; Carcinoma; Immunologic

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; SKIN CARCINOMA; T LYMPHOCYTE ACTIVATION; WOUND HEALING;

EID: 0036874966     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962002000600006     Document Type: Article

References (14)

1. Miller SJ. Etiology and Pathogenesis of basal cell carcinoma. Clin Dermatol 1995;13:527-36.
2. Festa-Neto C. Tumores cutâneos malignos In: Cucé LC, Festa Neto C. Manual de Dermatologia. Sâo Paulo: Atheneu, 2001:441-57
3. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MA, et. Al. A randomized, controlled, molecular study of condylomata acuminata clearence during treatment with imiquimod. J Infect Dis 1998;178:551-5.
4. Syed TA, Goswami J, Ahmad AS. Treatment of molluscum contagiosum in males with na analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998;25:309-13.
5. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basall cell carcinoma to the imune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
6. Mackenzie-Wood A, Kossard S, Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001;44:462-70.
7. Festa-Neto C. Aspectos imunológicos dos carcinomas basocelulares. Tese (Doutorado) - Faculdade de Medicina - Universidade de São Paulo, 1994.
8. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-11.
9. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, et al. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J Immunol 1995;155:2240-7.
10. Dahl MV. Imiquimod: na immune response modifier. J Am Acad Dermatol 2000;43:S1-5.
11. Suzuki H, Wang B, Amerio P, Toto P, Shivji GM, Miller RL, et al. Imiquimod, a novel topical immune response modifier, induces migration of Langerhans'cells. J Invest Dermatol 2000;114:135-41.
12. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000;26:577-9, p.56.
13. Sterry W, Bichel J, Andres K, Ginkel AM. Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: The 8th Congress on Cancers of the skin [abstracts] Zurich, July 18-21, 2001.
14. Marks R, Gebauer K, Shumack S, Amies M, BRYDEN j, Fox TL, Owens ML. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.